ESTRO 2025 - Abstract Book

S1878

Clinical - Urology

ESTRO 2025

Conclusion: Definitive RT is a safe and effective treatment for patients with localized PCa no matter their age. Although patients over 70 have higher risk factors and comorbidities, their bDFS, PCSS, and toxicities were comparable to those of patients aged <70 years.

Keywords: Age, prostate cancer, radiotherapy.

References: 1. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors-A systematic review. Eur Urol. 2023;84:191-206. 2. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29:235-41. 3. Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29:377-385. 4. Shaheen H, Salans MA, Mohamad O, Coleman PW, Ahmed S, Roach M, 3rd. Age 70 +/- 5 years and cancer-specific outcomes after treatment of localized prostate cancer: A systematic review. Int J Radiat Oncol Biol Phys. 2024;118:672-681.

137

Digital Poster Optimizing Treatment for Gleason 10 Prostate Cancer: Radiation Dose Escalation and PSMA-PET/CT Staging Cem Onal 1,2 , Ozan Cem Guler 1 , Birhan Demirhan 3 , Petek Erpolat 4 , Aysenur Elmali 2 , Melek Yavuz 2 1 Department of Radiation Oncologt, Baskent University Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey. 2 Department of Radiation Oncologt, Baskent University Faculty of Medicine, Ankara, Turkey. 3 Department of Radiation Oncologt, Iskenderun Gelisim Hospital, Hatay, Turkey. 4 Department of Radiation Oncologt, Gazi University Faculty of Medicine, Ankara, Turkey Purpose/Objective: To examine the impact of dose escalation through focal boost (FB) to intraprostatic lesion (IPL) and the use of prostate-membrane antigen positron emission tomography (PSMA-PET/CT) for staging in patients with Gleason score (GS) 10 prostate cancer (PCa) who received definitive radiotherapy (RT) and androgen deprivation therapy (ADT). Material/Methods: We retrospectively analyzed data on 92 patients with GS PCa who underwent definitive RT and ADT from March 2010 to October 2022. Freedom from biochemical failure (FFBF), prostate cancer-specific survival (PCSS), distant metastasis free survival (DMFS), and overall survival (OS) rates were calculated using the Kaplan−Meier method. The